title: Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
abstract: The 15th Conference on Retroviruses and Opportunistic Infections maintained its place as the premier meeting for presentation of the state of the art of antiretroviral therapy. This year brought together data on new antiretroviral agents in the pipeline, updated our knowledge base of agents approved in the past year (eg, maraviroc, raltegravir, etravirine), delineated approaches to management of treatment-naive and -experienced patients and the use of drugs for prevention of maternal-to-child transmission, and refined our expanding knowledge of drug resistance. A particular highlight of this year's conference was the progress made in antiretroviral treatment and research in resource-limited settings as reflected in both the number and quality of presentations emanating from the developing world.
authors.affiliation: Weill Medical College of Cornell University, New York, NY, USA.
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Wilkin
authors.forename: Barbara
authors.initials: B
authors.lastname: Taylor
authors.forename: Susan
authors.initials: S
authors.lastname: Olender
authors.forename: Scott M
authors.initials: SM
authors.lastname: Hammer
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D065100:CCR5 Receptor Antagonists; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015498:HIV-2 / Q000187:drug effects; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D009570:Nitriles; D010446:Peptide Fragments / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011247:Pregnancy; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D015700:HIV Envelope Protein gp41; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D009570:Nitriles; D010446:Peptide Fragments; D010879:Piperazines; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine; D000077560:Enfuvirtide; D000068898:Raltegravir Potassium; C486781:vicriviroc